Ignite Creation Date:
2024-05-06 @ 9:15 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02934932
Status:
TERMINATED
Last Update Posted:
2019-03-05
First Post:
2016-10-14
Brief Title:
A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated due to slow enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine if brexpiprazole treatment will be associated with a dose-dependent reduction in resting pupil diameter as a reflection of locus coeruleus LC norepinephrine NE neuron target engagement in a group of subjects with PTSD All subjects will be evaluated by physical examination ECG standard blood chemistry hematologic labs toxicology testing and urinalysis Results of these studies must demonstrate a lack of clinically significant abnormalities prior to enrollment Subjects will need to satisfy DSM-5 criteria for PTSD and receive a CAPS-5 score of 40 or greater on testing for study enrollment Resting pupil diameter during pupillometric evaluation after two weeks on each treatment will serve as the primary outcome measure This will be compared in the treatment groups using mixed effects repeated measures models to evaluate if there is a significant difference in pupil size among the treatments studied As a secondary analysis this approach will be used to evaluate whether there is treatment effect on total CAPS-5 score Lastly the investigators will compute correlations between pupil size and CAPS-5 scores
Detailed Description:
Primary Hypothesis Brexpiprazole treatment will be associated with dose-dependent reduction in resting pupil diameter as a reflection of LC NE neuron target engagement in a group of subjects with PTSD Secondary Hypothesis Brexpiprazole therapy will be associated with a dosedependent decrease in CAPS-5 scores Tertiary Hypothesis The pre-post treatment change in resting pupil diameter will be statistically significantly correlated with the pre-post change in CAPS-5 score
Subjects will be screened and will undergo pupil measures with rating scales on Visit 1 Subject must be free of all psychotropic medications for one week before Day 1 assessment except that prior FLX treatment will require 4 weeks of abstinence and MAOIs will require 2 weeks of abstinence They will be randomized to study drug an issued six weeks of study medication on Day 1 to take home A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 42 and undergo pupil measures with rating scales They will then undergo a one week washout period On Day 49 they will then be given another study drug to take home with rating scales and pupil measures obtained that day A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 91 and undergo pupil measures with rating scales They will then undergo a one week washout period On Day 98 they will then be given another study drug to take home with rating scales and pupil measures obtained that day A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 140 and undergo pupil measures with rating scales No more study medication will be provide on Day 140 and a final visit will be scheduled for on Day 147 one week later for and end of study interview with labs and physical exam At each visit other than the final visit subjects will complete the CAPS-5 MADRS Insomnia Severity Index and Clinician Assessment for Adverse Effects
Subjects will be screened and will undergo pupil measures with rating scales on Visit 1 Subject must be free of all psychotropic medications for one week before Day 1 assessment except that prior FLX treatment will require 4 weeks of abstinence and MAOIs will require 2 weeks of abstinence They will be randomized to study drug an issued six weeks of study medication on Day 1 to take home A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 42 and undergo pupil measures with rating scales They will then undergo a one week washout period On Day 49 they will then be given another study drug to take home with rating scales and pupil measures obtained that day A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 91 and undergo pupil measures with rating scales They will then undergo a one week washout period On Day 98 they will then be given another study drug to take home with rating scales and pupil measures obtained that day A phone call will then occur for safety assessment and medication adherence at every week They will present back to the study site on Day 140 and undergo pupil measures with rating scales No more study medication will be provide on Day 140 and a final visit will be scheduled for on Day 147 one week later for and end of study interview with labs and physical exam At each visit other than the final visit subjects will complete the CAPS-5 MADRS Insomnia Severity Index and Clinician Assessment for Adverse Effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None